12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dalbavancin: Completed Phase III enrollment

Durata completed enrollment in the double-blind, double-dummy, international Phase III DISCOVER-2 trial evaluating a single 1,000 mg dose of IV dalbavancin followed by a 500 mg dose given 1 week later in about 740 patients. Patients in the comparator arm will receive IV vancomycin and have the option...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >